{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:29:25Z","timestamp":1790861365659,"version":"4.1.0"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["15183"],"award-info":[{"award-number":["15183"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2020,1,7]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>The goal of treatment of chronic hepatitis C (HCV) is viral eradication. However,\nobtaining histological regression is even more important, because it will reduce the overall morbidity\nand mortality related to cirrhosis. Introduction of direct-acting antivirals (DAAs) in HCV improves\nrates of sustained virologic response (SVR). However, fibrosis regression has not been extensively\nassessed. The aim of this study was to detect the factors affecting fibrosis regression in chronic\nHCV patients treated with interferon containing regimens versus interferon-free DAA regimens.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This prospective observational cohort study was conducted at the Tropical Medicine and\nInfectious Diseases Department, Tanta University, Egypt, between October 2015 and December 2017.\nTransient elastography (FibroScan\u00ae) examination was performed before therapy, at SVR12, 6 months\nand 1 year after completing therapy for cured patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Reduction in fibrosis was reported in; 46.7% and 49.3% of patients with moderate fibrosis,\nand 89% and 78.7% of patients with advanced fibrosis after one year of interferon containing and interferon\nfree DAAs regimens respectively. Using multiple regression analysis; it was found that BMI,\ndegrees of hepatic stiffness and steatosis were related to regression of hepatic fibrosis after therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>DAAs with or without interferon resulted in a significant reduction of liver fibrosis. BMI,\nsteatosis and liver stiffness were independent factors for fibrosis regression in chronic HCV patients\ntreated with DAAs. Further studies are needed to explore the mechanism by which steatosis affects\nHCV related fibrosis regression after treatment with DAAs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871530319666190826150344","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T16:08:13Z","timestamp":1566835693000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study"],"prefix":"10.2174","volume":"20","author":[{"given":"Hanan","family":"Soliman","sequence":"first","affiliation":[{"name":"Department of Tropical Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ziada","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Salama","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Hamisa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab","family":"Badawi","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehad","family":"Hawash","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Selim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4366-2218","authenticated-orcid":true,"given":"Sherief","family":"Abd-Elsalam","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Tanta University, Tanta, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1001\/jama.289.18.2413","volume":"289","author":"Flamm S.L.","year":"2003","unstructured":"Flamm S.L.; Chronic hepatitis C virus infection. JAMA 2003,289(18),2413-2417","journal-title":"JAMA"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1871526519666181218104600","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Elsebaey M.A.; Fouad M.H.A.; Elkadeem M.; Badawi R.; Khayyal A.; Soliman S.; Negm M.S.; Abd-Elsalam S.; Outcomes of Treatment and Predictors of Response to Sofosbuvir plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection. Infect Disord Drug Targets Epub ahead of print2018,17","journal-title":"Infect Disord Drug Targets"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ajg.2014.04.003","volume":"15","author":"Waked I.","year":"2014","unstructured":"Waked I.; Doss W.; El-Sayed M.H.; Estes C.; Razavi H.; Shiha G.; Yosry A.; Esmat G.; The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014,15(2),45-52","journal-title":"Arab J Gastroenterol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/1871526517666170417143216","volume":"17","author":"Ahmed O.A.","year":"2017","unstructured":"Ahmed O.A.; Kaisar H.H.; Hawash N.; Samir H.; Shabana S.S.T.; Hassan A.; Fouad M.; Rizk F.; Abd-Elsalam S.; Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection. Infect Disord Drug Targets 2017,17(2),95-100","journal-title":"Infect Disord Drug Targets"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00705-017-3573-0","volume":"163","author":"Abd-Elsalam S.","year":"2018","unstructured":"Abd-Elsalam S.; Sharaf-Eldin M.; Soliman S.; Elfert A.; Badawi R.; Ahmad Y.K.; Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. Arch Virol 2018,163(1),51-56","journal-title":"Arch Virol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/IDR.S153060","volume":"11","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Kaisar H.H.; Badawi R.; Hawash N.; Samir H.; Shabana S.S.; Fouad M.H.A.; Rizk F.H.; Khodeir S.A.; Abd-Elsalam S.; Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 2018,11,295-298","journal-title":"Infect Drug Resist"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/IDR.S160593","volume":"11","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Elsebaey M.A.; Fouad M.H.A.; Elashry H.; Elshafie A.I.; Elhadidy A.A.; Esheba N.E.; Elnaggar M.H.; Soliman S.; Abd-Elsalam S.; Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist 2018,11,441-445","journal-title":"Infect Drug Resist"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9616234","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Safwat E.; Khalifa M.O.; Elshafie A.I.; Fouad M.H.A.; Salama M.M.; Naguib G.G.; Eltabbakh M.M.; Sherief A.F.; Abd-Elsalam S.; Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: An Experiment the Size of Egyptian Village. Int J Hepatol 2018","journal-title":"Int J Hepatol"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.2174\/1871526518666180912121835","volume":"\u2022","author":"Abd-Elsalam S.","year":"2018","unstructured":"Abd-Elsalam S.; Badawi R.; Elnawasany S.; Yousef M.; Mansour L.; Hawash N.; Elkhouly R.A.; Soliman S.; Selim A.; Kobtan A.; Elfert A.; Sofosbuvir, pegylated interferon and ribavirin in treatment of an Egyptian cohort with hepatitis C virus infection in real life clinical practice. Infect Disord Drug Targets Epub ahead of print2018,\u2022","journal-title":"Infect Disord Drug Targets"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jhep.2010.11.016","volume":"54","author":"Khattab M.A.","year":"2011","unstructured":"Khattab M.A.; Ferenci P.; Hadziyannis S.J.; Colombo M.; Manns M.P.; Almasio P.L.; Esteban R.; Abdo A.A.; Harrison S.A.; Ibrahim N.; Cacoub P.; Eslam M.; Lee S.S.; Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011,54(6),1250-1262","journal-title":"J Hepatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejrnm.2015.12.007","volume":"47","author":"El Saadany S.","year":"2016","unstructured":"El Saadany S.; Soliman H.; Ziada D.H.; Hamisa M.; Hefeda M.; Selim A.; Goraba H.; Fibroscan versus liver biopsy in the evaluation of response among the Egyptian HCV infected patients to treatment. Egyptian Journal of Radiology and Nuclear Medicine 2016,47,1-7","journal-title":"Egyptian Journal of Radiology and Nuclear Medicine"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/hep.20425","volume":"40","author":"Parsons C.J.","year":"2004","unstructured":"Parsons C.J.; Bradford B.U.; Pan C.Q.; Cheung E.; Schauer M.; Knorr A.; Krebs B.; Kraft S.; Zahn S.; Brocks B.; Feirt N.; Mei B.; Cho M.S.; Ramamoorthi R.; Roldan G.; Ng P.; Lum P.; Hirth-Dietrich C.; Tomkinson A.; Brenner D.A.; Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 2004,40(5),1106-1115","journal-title":"Hepatology"},{"key":"ref=13","first-page":"919","volume":"33","author":"Yang H.X.","year":"2008","unstructured":"Yang H.X.; Yi Y.R.; [Curative effect of interferon-alpha on rat liver fibrosis induced by CCl4] Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008,33(10),919-925","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hep.27366","volume":"61","author":"Yoshida E.M.","year":"2015","unstructured":"Yoshida E.M.; Sulkowski M.S.; Gane E.J.; Herring R.W.; Ratziu V.; Ding X.; Wang J.; Chuang S.M.; Ma J.; McNally J.; Stamm L.M.; Brainard D.M.; Symonds W.T.; McHutchison J.G.; Beavers K.L.; Jacobson I.M.; Reddy K.R.; Lawitz E.; Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015,61(1),41-45","journal-title":"Hepatology"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"van der Meer A.J.","year":"2012","unstructured":"van der Meer A.J.; Veldt B.J.; Feld J.J.; Wedemeyer H.; Dufour J.F.; Lammert F.; Duarte-Rojo A.; Heathcote E.J.; Manns M.P.; Kuske L.; Zeuzem S.; Hofmann W.P.; de Knegt R.J.; Hansen B.E.; Janssen H.L.; Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012,308(24),2584-2593","journal-title":"JAMA"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/cid\/cit234","volume":"57","author":"Aleman S.","year":"2013","unstructured":"Aleman S.; Rahbin N.; Weiland O.; Davidsdottir L.; Hedenstierna M.; Rose N.; Verbaan H.; St\u00e5l P.; Carlsson T.; Norrgren H.; Ekbom A.; Granath F.; Hultcrantz R.; A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013,57(2),230-236","journal-title":"Clin Infect Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","volume":"149","author":"Mallet V.","year":"2008","unstructured":"Mallet V.; Gilgenkrantz H.; Serpaggi J.; Verkarre V.; Vallet-Pichard A.; Fontaine H.; Pol S.; Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008,149(6),399-403","journal-title":"Ann Intern Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/hep.20717","volume":"41","author":"Lackner C.","year":"2005","unstructured":"Lackner C.; Struber G.; Liegl B.; Leibl S.; Ofner P.; Bankuti C.; Bauer B.; Stauber R.E.; Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005,41(6),1376-1382","journal-title":"Hepatology"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.007","volume":"141","author":"Hoefs J.C.","year":"2011","unstructured":"Hoefs J.C.; Shiffman M.L.; Goodman Z.D.; Kleiner D.E.; Dienstag J.L.; Stoddard A.M.; Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology 900-908.e1, 2.2011,141(3)","journal-title":"Gastroenterology"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/jgh.13758","volume":"32","author":"Elsharkawy A.","year":"2017","unstructured":"Elsharkawy A.; Alem S.A.; Fouad R.; El Raziky M.; El Akel W.; Abdo M.; Tantawi O.; AbdAllah, M.; Bourliere, M.; Esmat, G. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol 2017,32(9),1624-1630","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3126\/jcmsn.v13i3.17852","volume":"13","author":"Sharma D.","year":"2017","unstructured":"Sharma D.; Sudhamshu K.C.; Shrestha A.; Jaishi B.; Status of liver stiffness following directly acting antiviral treatment in patients with chronic hepatitis C: A Nepalese study. Journal of College of Medical Sciences-Nepal 2017,13(3),302-305","journal-title":"Journal of College of Medical Sciences-Nepal"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179400","volume":"12","author":"Mascia C.","year":"2017","unstructured":"Mascia C.; Vita S.; Zuccal\u00e0 P.; Marocco R.; Tieghi T.; Savinelli S.; Rossi R.; Iannetta M.; Pozzetto I.; Furlan C.; Mengoni F.; Mastroianni C.M.; Vullo V.; Lichtner M.; Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon. PLoS One 2017,12(6)","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/HMER.S7394","volume":"2","author":"Mueller S.","year":"2010","unstructured":"Mueller S.; Sandrin L.; Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med 2010,2,49-67","journal-title":"Hepat Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1053\/j.gastro.2017.02.037","volume":"152","author":"Comarmond C.","year":"2017","unstructured":"Comarmond C.; Garrido M.; Pol S.; Desbois A.C.; Costopoulos M.; Le Garff-Tavernier M.; Si Ahmed S.N.; Alric L.; Fontaine H.; Bellier B.; Maciejewski A.; Rosenzwajg M.; Klatzmann D.; Musset L.; Poynard T.; Cacoub P.; Saadoun D.; Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. Gastroenterology 2017,152(8),2052-2062.e2","journal-title":"Gastroenterology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/jmv.25310","volume":"91","author":"Sasaki R.","year":"2019","unstructured":"Sasaki R.; Meyer K.; Moriyama M.; Kato N.; Yokosuka O.; Ray R.B.; Aurora R.; Ray R.; Kanda T.; Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients. J Med Virol 2019,91(3),411-418","journal-title":"J Med Virol"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159413","volume":"11","author":"Chekuri S.","year":"2016","unstructured":"Chekuri S.; Nickerson J.; Bichoupan K.; Sefcik R.; Doobay K.; Chang S.; DelBello D.; Harty A.; Dieterich D.T.; Perumalswami P.V.; Branch A.D.; Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus. PLoS One 2016,11(7)","journal-title":"PLoS One"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5455\/msm.2014.26.172-176","volume":"26","author":"Vukobrat-Bijedic Z.","year":"2014","unstructured":"Vukobrat-Bijedic Z.; Husic-Selimovic A.; Mehinovic L.; Mehmedovic A.; Junuzovic D.; Bjelogrlic I.; Sofic A.; Djurovic A.; Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed 2014,26(3),172-176","journal-title":"Mater Sociomed"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0168-8278(06)80599-4","volume":"44","author":"Par A.","year":"2006","unstructured":"Par A.; Par P.G.; Berki T.; Miseta A.; Hegedus G.; Mozsyk G.; Hunyady B.; Peg-IFN plus ribavirin therapy suppresses plasma TGF-1 beta, hyaluronic acid and procollagen-III peptide levels in patients with chronic hepatitis C independently of virological response. J Hepatol 2006,44(2),222","journal-title":"J Hepatol"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003853","volume":"95","author":"Abd-Elsalam S.","year":"2016","unstructured":"Abd-Elsalam S.; Habba E.; Elkhalawany W.; Tawfeek S.; Elbatea H.; El-Kalla F.; Soliman H.; Soliman S.; Yousef M.; Kobtan A.; El Nawasany S.; Awny S.; Amer I.; Mansour L.; Rizk F.; Correlation of platelets count with endoscopic findings in a cohort of Egyptian patients with liver cirrhosis. Medicine (Baltimore) 2016,95(23)","journal-title":"Medicine (Baltimore)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.gie.2016.12.026","volume":"86","author":"Mansour L.","year":"2017","unstructured":"Mansour L.; El-Kalla F.; El-Bassat H.; Abd-Elsalam S.; El-Bedewy M.; Kobtan A.; Badawi R.; Elhendawy M.; Randomized controlled trial of scleroligation versus band ligation alone for eradication of gastroesophageal varices. Gastrointest Endosc 2017,86(2),307-315","journal-title":"Gastrointest Endosc"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/174459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T23:27:37Z","timestamp":1581377257000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/174459\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530319666190826150344","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}